3SBio raises over HK$3 bn in share placing for strategic growth

3SBio Inc. announced the successful completion of its share placing under a general mandate on December 9, 2025. The company placed 105,169,500 new shares at HK$29.62 per share, representing approximately 4.14% of its enlarged issued share capital. This initiative, facilitated by Morgan Stanley as the sole overall coordinator, global coordinator, and bookrunner, generated net proceeds of approximately HK$3,086.84 million.

The proceeds will primarily support 3SBio's strategic growth over the next three years. Approximately 80% (HK$2,469.47 million) is allocated to R&D-related expenditures, including advancing clinical research for innovative drug candidates and expanding indications for commercialized drugs. The remaining 20% (HK$617.37 million) will be used for working capital and general corporate purposes.

Following the placing, the public float of 3SBio Inc. remains above 25% of the company's enlarged issued share capital. The total number of shares in issue increased from 2,432,833,912 to 2,538,003,412.